Leerink Partnrs Predicts Nkarta FY2029 Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Nkarta in a report issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch forecasts that the company will earn ($1.74) per share for the year. The consensus estimate for Nkarta’s current full-year earnings is ($1.68) per share.

Several other research analysts have also weighed in on NKTX. HC Wainwright dropped their price target on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Mizuho reduced their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research report on Thursday, November 21st. Finally, Needham & Company LLC lowered their price objective on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $15.00.

Nkarta Stock Up 2.4 %

NKTX opened at $2.12 on Friday. The firm has a market capitalization of $149.61 million, a P/E ratio of -1.13 and a beta of 0.85. The stock has a fifty day moving average of $2.36 and a 200-day moving average of $3.66. Nkarta has a 12-month low of $1.96 and a 12-month high of $16.24.

Institutional Trading of Nkarta

Large investors have recently made changes to their positions in the stock. Invesco Ltd. acquired a new stake in Nkarta in the 4th quarter worth approximately $30,000. Sequoia Financial Advisors LLC bought a new position in shares of Nkarta in the fourth quarter valued at approximately $31,000. Erste Asset Management GmbH bought a new position in shares of Nkarta in the third quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Nkarta in the fourth quarter worth $37,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Nkarta by 110.9% during the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after buying an additional 5,243 shares during the period. Institutional investors own 80.54% of the company’s stock.

Insider Activity

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 8.70% of the stock is owned by insiders.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.